Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors
Open Access
- 20 October 2009
- journal article
- Published by Springer Nature in British Journal of Cancer
- Vol. 101 (10) , 1717-1723
- https://doi.org/10.1038/sj.bjc.6605366
Abstract
Background: Methods: Results: Conclusion:Keywords
This publication has 27 references indexed in Scilit:
- Drug Target Identification Using Side-Effect SimilarityScience, 2008
- A quantitative analysis of kinase inhibitor selectivityNature Biotechnology, 2008
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Targeting Tyrosine Kinases in Cancer: The Second WaveScience, 2006
- Mechanisms of drug inhibition of signalling moleculesNature, 2006
- Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2006
- Elucidating mechanisms of drug-induced toxicityNature Reviews Drug Discovery, 2005
- Heterozygous embryonic lethality induced by targeted inactivation of the VEGF geneNature, 1996
- Failure of blood-island formation and vasculogenesis in Flk-1-deficient miceNature, 1995
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973